Feb. 03, 2025 Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, announced today it has closed a EUR 7 million financing. The funding round was led by new investors Fåhraeus Startup and Growth AB (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund. FSG and EIC Fund were joined by leading Finnish inve

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan’s ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Feb. 04, 2025 -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology comp

Auron Therapeutics公司今日宣布，该公司完成2700万美元的B轮融资。同时，其潜在“first-in-class”的KAT2A/B蛋白降解剂AUTX-703的IND申请已经获得美国FDA的许可。该公司正在启动AUTX-703治疗血液恶性肿瘤的临床试验。 本次B轮融资由DCVC Bio领投，并得到了Apollo Health Ventures、Arkin Bio Ventures、BrightEdge、Casdin Capital、Franklin Berger、Mubadala Capital、Polaris Partners以及启明创投美国部的支持。 融资获得的资金将用于推进AUTX-703在急性髓系白血病（AML）患者中进行的1期临床概念验证试验，该试验将于今年第一季度开始患者招募。此外，部分资金还将用于评估靶向KAT2A/B在治疗自身免疫性疾病中的潜力，并推动利用该公司独有的AURIGIN药物发现平台针对上皮间质转化（EMT）肿瘤靶点的药物研发工作。 AUTX-703是一款潜在“first-in-class”口服KAT2A/B蛋白降解剂，由Auron通过其A

Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair Funding recognises Harness’ significant progress in unexplored targets for CNS disease and accelerates selection of clinical candidate for lead programme (FAN1) in Huntington’s Disease Harness’ unique approach builds on recent research published in Nature Medicine and Cell 27 January 2025: Harness Therapeutics (‘Harness’), a biotechno

近日，微光基因宣布完成Pre-A轮融资，融资总额达到数千万元人民币。此次融资将助力微光基因快速推进针对未满足临床需求的常见病表观遗传编辑管线研究。 目前，微光基因聚力从生命源头探索疾病治愈方案，专注于多元化常见病的管线布局。杰出的研发团队，突破性的底层表观遗传编辑技术和成熟的递送打造出极具潜力的药界新星。 微光基因已实现从底层工具平台到下游药物开发全流程覆盖，不断优化微光基因编辑的分子利剑；依托清晰的自主IP布局全球市场，同时积极拓展对外合作，竭力为全球患者贡献微光基因“一针即愈”的基因治疗方案，打造“立足中国，走向全球”的体内基因表观遗传编辑品牌。微光基因表示，本次融资完成以后将加快速推进核心管线临床研究，同时布局多个全球first-in-class管线。 微光基因CEO胡洋博士表示：非常感谢新老股东对微光基因及团队的肯定和支持。微光基因以创新为驱动，布局全球领先的体内基因编辑技术，专注于通过RNP/mRNA-VLP/LNP递送系统开发新一代体内基因编辑药物，为患者提供更优治疗选择。 内容来源于网络，如有侵权，请联系删除。

Jan. 21, 2025 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced today announced it has entered into agreements with certain holders of its existing warrants exercisable for 4,971,110 shares of its common stock, in the aggregate, to exercise outstanding warrants at a reduced exercise price of $0.751 per share, in exchange for new warr

January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accom

Jan. 15, 2025 -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among others. The proceeds will support entry of the Company’s lead product candidate, HB2198, into a Phase 1 clinical trial in patients living with Systemic Lupus Erythematosus (“Lupus”) as well as development of additional therapeutics from Hinge Bio’s proprietary GEM-DIMER

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IND-enablement of bispecifics Lead program is a phase 2-ready, long-acting anti-TSLP monoclonal antibody with potential to be first-to-market with dosing every 6 months Building a discovery pipeline of long-acting bispecifics harnessing validated targets and syn

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development Jan. 09, 2025 -- Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today the closing of an oversubscribed CHF 50 million (approx